At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 375 enrolled
Drug / intervention
MT-8554 1mg +3 moredrug
Likely dose
MT-8554 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of MT-8554 on the Frequency and Severity of Vasomotor Symptoms in Postmenopausal Women
In Brief
A Phase 2 clinical trial evaluating MT-8554 1mg, MT-8554 5mg, and 2 other interventions for Menopause Hot Flashes. Completed, enrolled 375 participants across 63 sites.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of MT-8554 for treatment of vasomotor symptoms (VMS) associated with menopause.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMenopause Hot Flashes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartOct 2017
Primary CompletionOct 2018
Study CompletionNov 2018
TodayJul 2026
First PostedSep 25, 2017
Enrollment StartOct 9, 2017
Primary CompletionOct 19, 2018
Study CompletionNov 9, 2018
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 8.8 years ago
Interventions
MT-8554 1mgdrug
MT-8554 1mg QD, oral, 12 weeks
MT-8554 5mgdrug
MT-8554 5mg QD, oral, 12 weeks
MT-8554 10mgdrug
MT-8554 10mg QD, oral, 12 weeks
Placebodrug
Placebo QD, oral, 12 weeks